Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine extended release - Pacira BioSciences

Drug Profile

Bupivacaine extended release - Pacira BioSciences

Alternative Names: Bupivacaine extended-release - Pacira BioSciences; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma Inc
  • Developer Nuance Biotech; Pacira BioSciences; Pacira Pharmaceuticals
  • Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Anaesthesia; Postoperative pain
  • Phase III Dental pain
  • No development reported Musculoskeletal pain; Pain

Most Recent Events

  • 16 Feb 2024 Efficacy and adverse events data from a phase III STRIDE trial in Postoperative pain released by Pacira Pharmaceuticals
  • 31 Dec 2023 Pacira BioSciences has patent protection for EXPAREL® in USA, Europe, China, Israel and Japan
  • 31 Dec 2023 Pacira BioSciences plans to commercialise Exparel® for Postoperative pain (In adolescents, In children)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top